JP4836044B2 - Oral amino acid acne treatment - Google Patents
Oral amino acid acne treatment Download PDFInfo
- Publication number
- JP4836044B2 JP4836044B2 JP2004110487A JP2004110487A JP4836044B2 JP 4836044 B2 JP4836044 B2 JP 4836044B2 JP 2004110487 A JP2004110487 A JP 2004110487A JP 2004110487 A JP2004110487 A JP 2004110487A JP 4836044 B2 JP4836044 B2 JP 4836044B2
- Authority
- JP
- Japan
- Prior art keywords
- parts
- mass
- acne
- amino acid
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims description 80
- 206010000496 acne Diseases 0.000 title claims description 80
- 150000001413 amino acids Chemical class 0.000 title claims description 78
- 229940024606 amino acid Drugs 0.000 claims description 77
- 235000001014 amino acid Nutrition 0.000 claims description 77
- 239000003814 drug Substances 0.000 claims description 30
- 229940124597 therapeutic agent Drugs 0.000 claims description 28
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 12
- 229930064664 L-arginine Natural products 0.000 claims description 12
- 235000014852 L-arginine Nutrition 0.000 claims description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 11
- 239000004395 L-leucine Substances 0.000 claims description 11
- 235000019454 L-leucine Nutrition 0.000 claims description 11
- 229960000310 isoleucine Drugs 0.000 claims description 11
- 229960003136 leucine Drugs 0.000 claims description 11
- 229960004295 valine Drugs 0.000 claims description 11
- 229930182844 L-isoleucine Natural products 0.000 claims description 10
- 229930182816 L-glutamine Natural products 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
- 229930182821 L-proline Natural products 0.000 claims description 8
- 229960002743 glutamine Drugs 0.000 claims description 8
- 229960002429 proline Drugs 0.000 claims description 8
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- -1 L-rigid Chemical compound 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002910 effect on acne Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009736 adult acne Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、有効成分として特定のアミノ酸を特定の割合で含有するニキビの治療に有効なアミノ酸組成物、すなわち、(a)5種のアミノ酸を有効成分として含有する、すなわち、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシンおよびL−ロイシンの5種のアミノ酸を、それぞれ、10〜40質量部、10〜40質量部、5〜20質量部、8〜30質量部および10〜35質量部の割合で含有することを特徴とする経口アミノ酸ニキビ治療剤、このようなニキビ治療剤と外用ニキビ治療剤の組合せからなるニキビ治療剤のキット、およびこのようなニキビ治療剤と外用ニキビ治療剤とを併用するニキビ治療方法、(b)前記5種のアミノ酸を含む8種のアミノ酸を有効成分として含有する、すなわち、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシン、L−ロイシン、L−プロリン、Dおよび/またはL−アラニンおよびグリシンの8種のアミノ酸を、それぞれ、10〜40質量部、10〜40質量部、5〜20質量部、8〜30質量部、10〜35質量部、2〜10質量部、2〜16質量部および0.5〜8質量部の割合で含有することを特徴とする経口アミノ酸ニキビ治療剤、このようなニキビ治療剤と外用ニキビ治療剤の組合せからなるニキビ治療剤のキット、およびこのようなニキビ治療剤と外用ニキビ治療剤とを併用するニキビ治療方法、ならびに(c)前記5種のアミノ酸を含む12種のアミノ酸を有効成分として含有する、すなわち、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシン、L−ロイシン、L−リジン、L−メチオニン、L−スレオニン、L−ヒスチジン、L−プロリン、L−フェニルアラニンおよびL−トリプトファンの12種のアミノ酸を、それぞれ、10〜40質量部、10〜40質量部、5〜20質量部、8〜30質量部、10〜35質量部、2〜10質量部、2〜20質量部、4〜15質量部、2〜10質量部、2〜10質量部、0.2〜10質量部および0.4〜4質量部の割合で含有することを特徴とする経口アミノ酸ニキビ治療剤、ならびにこのようなニキビ治療剤と外用ニキビ治療剤の組合せからなるニキビ治療剤のキット、およびこのようなニキビ治療剤と外用ニキビ治療剤とを併用するニキビ治療方法に関する。 The present invention provides an amino acid composition effective for treating acne containing a specific amino acid at a specific ratio as an active ingredient, that is, (a) containing five kinds of amino acids as active ingredients, that is, L-arginine, L -5 types of amino acids of glutamine, L-valine, L-isoleucine and L-leucine are 10 to 40 parts by weight, 10 to 40 parts by weight, 5 to 20 parts by weight, 8 to 30 parts by weight and 10 to 35 parts, respectively. An oral amino acid acne therapeutic agent characterized by containing in parts by mass, a kit of an acne therapeutic agent comprising a combination of such an acne therapeutic agent and an external acne therapeutic agent, and such an acne therapeutic agent and an external acne treatment A method for treating acne in combination with an agent, (b) containing 8 amino acids including the 5 amino acids as active ingredients, ie, L-arginine, L Eight types of amino acids of glutamine, L-valine, L-isoleucine, L-leucine, L-proline, D and / or L-alanine and glycine are 10 to 40 parts by mass, 10 to 40 parts by mass, 20 mass parts, 8-30 mass parts, 10-35 mass parts, 2-10 mass parts, 2-16 mass parts, and the content of 0.5-16 mass parts, The oral amino acid acne therapeutic agent characterized by the above-mentioned , A kit for acne treatment comprising a combination of such an acne treatment agent and an external acne treatment agent, an acne treatment method using such an acne treatment agent and an external acne treatment agent in combination, and (c) the above five types 12 kinds of amino acids including amino acids are contained as active ingredients, that is, L-arginine, L-glutamine, L-valine, L-isoleucine, L-leucine, L-rigid , L-methionine, L-threonine, L-histidine, L-proline, L-phenylalanine and L-tryptophan, 12 kinds of amino acids, 10 to 40 parts by weight, 10 to 40 parts by weight, 5 to 20 parts by weight, respectively 8-30 mass parts, 10-35 mass parts, 2-10 mass parts, 2-20 mass parts, 4-15 mass parts, 2-10 mass parts, 2-10 mass parts, 0.2-10 mass parts And an oral amino acid acne therapeutic agent characterized by containing 0.4 to 4 parts by mass, and a kit for acne therapeutic agent comprising a combination of such an acne therapeutic agent and an external acne therapeutic agent, and such The present invention relates to a method for treating acne using a combination of an acne treatment agent and an external acne treatment agent.
ニキビは90%以上の青年男女が経験するとされる皮膚疾患であるが、思春期の生理現象ということで、かつては積極的な治療がされていなかった。しかし、最近では、思春期を過ぎてのニキビも大人のニキビとして注目されている。 Acne is a skin disease that more than 90% of adolescent men and women will experience, but because it is an adolescent physiological phenomenon, it has not been treated aggressively. Recently, however, acne after puberty has attracted attention as adult acne.
ニキビは脂腺性毛包を侵す慢性炎症性疾患で、主として思春期に発症し、その病因は内因性、外因性因子が数多く複雑に関連し合っている。また、その発症機序にはいくつかの段階があり、大きく二つの段階に分けることができる。第一段階は面ほう形成であり、第二段階は炎症惹起である。このうち面ほう形成過程では、1)主として男性ホルモン作用による皮脂分泌の亢進、2)毛嚢漏斗部の角化異常、3)毛包内細菌による皮脂中の中性脂肪の遊離脂肪酸への分解亢進が、また炎症惹起過程では、P. acnes由来の細胞外炎症誘発物質、とくに好中球遊走化因子が重要である。 Acne is a chronic inflammatory disease that affects sebaceous hair follicles and develops mainly in puberty. Its etiology is intrinsically related to many exogenous factors. There are several stages in the onset mechanism, and it can be roughly divided into two stages. The first stage is surface formation and the second stage is inflammation. Among these, in the process of surface formation, 1) increased sebum secretion mainly due to male hormone action, 2) abnormal keratinization of hair follicle funnel, and 3) degradation of neutral fat in sebum into free fatty acids by bacteria in hair follicles. In the process of promoting inflammation and inducing inflammation, P. acnes-derived extracellular inflammation-inducing substances, particularly neutrophil chemotactic factors are important.
ニキビの発生段階に合わせて、治療法は異なる。非炎症性の皮疹である面ほうに対してはイオウ局所外用療法が基本であり、原則的に全身内服(経口)療法は行わない。特に、イオウ含有ローションはその刺激作用により角質の剥離を起こし、軽症のニキビを改善させる。また、特殊な治療法として、総合代謝性ホルモン剤や経口避妊薬の全身内服(経口)療法もある。炎症性の皮疹である赤色丘疹、膿ほうに対しては局所外用療法および全身内服(経口)療法が主体となる。局所外用療薬としては非ステロイド系抗炎症外用剤、外用抗菌剤、そして、経口薬としては抗菌剤や漢方薬が用いられる。 Treatment varies depending on the stage of acne. Topical sulfur therapy is fundamental for non-inflammatory skin eruptions, and systemic (oral) therapy is not performed in principle. In particular, a sulfur-containing lotion causes exfoliation of the keratin due to its stimulating action and improves mild acne. In addition, as a special treatment, there are systemic oral (oral) therapies of comprehensive metabolic hormones and oral contraceptives. For red papules and pus, which are inflammatory eruptions, local topical therapy and systemic (oral) therapy are mainly used. Non-steroidal anti-inflammatory external preparations and external antibacterial agents are used as topical external medicines, and antibacterial agents and traditional Chinese medicines are used as oral preparations.
しかしながら、これらの方法は、皮膚科医の診察を受けた後に取られる手法であり、欧米人に比べて比較的軽症のニキビが多い日本人では、薬局で市販薬を購入するなどして自己治療している場合が多く見られる。また、補助的全身内服(経口)療法としてビタミン剤、便通調整剤、精神安定剤などが用いられることがある。ビタミンに関してはその有効量がビタミンA 300,000〜400,000国際単位/日、ビタミンB6 30〜60mg/日、そしてビタミンE 150〜300mg/日のように多量のビタミンが必要とされ、ビタミンAに関しては副作用も心配される。市販されているものでは、エーザイ株式会社製「チョコラBBエース」のようなビタミンB群複合剤(参考文献:基礎と臨床、16(11)、495(1982))やカネボウ薬品社製「ヨクイノーゲン」のような漢方剤とビタミンの複合剤(参考文献:基礎と臨床、21(6)、565(1987))などが、内服によりニキビ症状に効果があることが報告されている。しかし、アミノ酸を利用した例は全く知られていなかった。 However, these methods are taken after consulting a dermatologist. For Japanese people with relatively mild acne compared to Westerners, self-treatment such as purchasing over-the-counter drugs at pharmacies Many cases are seen. In addition, vitamins, fecal adjustment agents, tranquilizers, etc. may be used as auxiliary systemic (oral) therapy. For vitamins, effective amounts of vitamin A 300,000-400,000 international units / day, vitamin B 6 30-60 mg / day, and vitamin E 150-300 mg / day are required in large quantities, Regarding A, side effects are also a concern. Commercially available products include vitamin B complex (such as “Chocola BB ace” manufactured by Eisai Co., Ltd. (reference: basic and clinical, 16 (11), 495 (1982)) and “Yokuinogen” manufactured by Kanebo Pharmaceutical Co., Ltd. It has been reported that Chinese medicine and vitamin combination agents such as (reference: basic and clinical, 21 (6), 565 (1987)) have an effect on acne symptoms by internal use. However, no examples using amino acids have been known.
さて、本発明者は、多年各種アミノ酸類の栄養作用や生理作用の研究に従事し、その間、特定のアミノ酸の特定の割合の組成物が栄養状態の改善に有効なことを見出し(後掲特許文献1)、あるいはまた育毛作用に優れることを見出し、これについては既に特許出願をしている(特願2003−199038)。しかしながら、ニキビに対してアミノ酸が効果を示すという知見はなかった。
前項記載の従来技術の背景下に、本発明は優れたニキビ治療剤、ならびにそれらを利用するニキビ治療法の提供を目的とする。 In view of the background of the prior art described in the preceding paragraph, the present invention aims to provide an excellent acne treatment agent and an acne treatment method using the same.
本発明者は、先に説明したように、各種アミノ酸類の栄養作用や生理作用の研究に長年従事してきたところ、特定のアミノ酸を特定の割合で経口摂取すればニキビ治療に有効であることを見出し、このような知見に基づいて本発明を完成した。 As described above, the present inventor has been engaged in research on the nutritional and physiological effects of various amino acids for many years, and it is effective for acne treatment if a specific amino acid is orally ingested at a specific ratio. The present invention was completed based on the finding and such findings.
すなわち、本発明は、先に説明したように、有効成分として特定のアミノ酸を特定の割合で含有するニキビ治療に有効なアミノ酸組成物、すなわち、(a)L−アルギニン、L−グルタミン、L−バリン、L−イソロイシンおよびL−ロイシンの5種のアミノ酸を、それぞれ、10〜40質量部、10〜40質量部、5〜20質量部、8〜30質量部および10〜35質量部の割合で含有することを特徴とする経口アミノ酸ニキビ治療剤、(b)前記5種のアミノ酸を含む8種のアミノ酸を有効成分として含有する、すなわち、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシン、L−ロイシン、L−プロリン、Dおよび/またはL−アラニンおよびグリシンの8種のアミノ酸を、それぞれ、10〜40質量部、10〜40質量部、5〜20質量部、8〜30質量部、10〜35質量部、2〜10質量部、2〜16質量部および0.5〜8質量部の割合で含有することを特徴とする経口アミノ酸ニキビ治療剤、(c)前記5種のアミノ酸を含む12種のアミノ酸を有効成分として含有する、すなわち、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシン、L−ロイシン、L−リジン、L−メチオニン、L−スレオニン、L−ヒスチジン、L−プロリン、L−フェニルアラニンおよびL−トリプトファンの12種のアミノ酸を、それぞれ、10〜40質量部、10〜40質量部、5〜20質量部、8〜30質量部、10〜35質量部、2〜10質量部、2〜20質量部、4〜15質量部、2〜10質量部、2〜10質量部、0.2〜10質量部および0.4〜4質量部の割合で含有することを特徴とする経口アミノ酸ニキビ治療剤に関する。本発明は、また、このような経口ニキビ治療剤と外用ニキビ治療剤よりなるニキビ治療剤のキットに関し、さらにこのような経口ニキビ治療剤と外用ニキビ治療剤を併用するニキビ治療方法に関する。 That is, as described above, the present invention provides an amino acid composition effective for acne treatment containing a specific amino acid in a specific ratio as an active ingredient, that is, (a) L-arginine, L-glutamine, L- Five amino acids of valine, L-isoleucine and L-leucine are respectively used in proportions of 10 to 40 parts by weight, 10 to 40 parts by weight, 5 to 20 parts by weight, 8 to 30 parts by weight and 10 to 35 parts by weight. (B) containing eight amino acids including the above-mentioned five amino acids as active ingredients, that is, L-arginine, L-glutamine, L-valine, L- 8 kinds of amino acids of isoleucine, L-leucine, L-proline, D and / or L-alanine and glycine are 10 to 40 parts by mass and 10 to 40 parts, respectively. , 5 to 20 parts by weight, 8 to 30 parts by weight, 10 to 35 parts by weight, 2 to 10 parts by weight, 2 to 16 parts by weight, and 0.5 to 8 parts by weight. Amino acid acne therapeutic agent, (c) containing 12 amino acids including the above 5 amino acids as active ingredients, that is, L-arginine, L-glutamine, L-valine, L-isoleucine, L-leucine, L- 12 kinds of amino acids of lysine, L-methionine, L-threonine, L-histidine, L-proline, L-phenylalanine and L-tryptophan are respectively 10 to 40 parts by mass, 10 to 40 parts by mass and 5 to 20 parts by mass. Parts, 8-30 parts by mass, 10-35 parts by mass, 2-10 parts by mass, 2-20 parts by mass, 4-15 parts by mass, 2-10 parts by mass, 2-10 parts by mass, 0.2-10 parts by mass Part and 0 Be contained in an amount of 4-4 parts by weight relates to an oral amino acne treatment agent characterized. The present invention also relates to an acne therapeutic agent kit comprising such an oral acne therapeutic agent and an external acne therapeutic agent, and further relates to an acne treatment method using such an oral acne therapeutic agent and an external acne therapeutic agent in combination.
以下、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail.
本発明の経口アミノ酸ニキビ治療剤の調製には特別の制限や困難はなく、所定のアミノ酸を所定の割合で含有せしめることを除いては、適宜常法に準ずることができる。 There are no particular limitations or difficulties in preparing the therapeutic agent for oral amino acid acne of the present invention, and it can be appropriately applied in accordance with conventional methods except that a predetermined amino acid is contained in a predetermined ratio.
本発明の経口アミノ酸ニキビ治療剤は、上記所定の5種、8種又は12種のアミノ酸を上記所定の割合で単に混合して調製する他に、適宜の添加剤を使用して常法により調製することもできる。このような添加剤としては、味を調整改良する果汁、デキストリン、環状オリゴ糖、糖類(果糖ぶどう糖液糖、ショ糖)、酸味料、香料、抹茶粉末など、テクスチャーを改善する乳化剤、コラーゲン、全脂粉乳、増粘多糖類や寒天(ゼリー飲料の場合)など、更には前記5種、8種又は12種のアミノ酸以外のアミノ酸、ビタミン類、卵殻カルシウム、パントテン酸カルシウム、その他のミネラル類、ローヤルゼリー、プロポリス、蜂蜜、食物繊維、アガリクス、キチン、キトサン、漢方生薬、コンドロイチン、カプサイシンなどの通常健康食品の成分として使用されているものを挙げることができる。 The oral amino acid acne treatment agent of the present invention is prepared by a conventional method using appropriate additives in addition to the above-mentioned predetermined 5, 8, or 12 amino acids simply mixed at the above-mentioned predetermined ratio. You can also Such additives include fruit juice, dextrin, cyclic oligosaccharides, sugars (fructose glucose liquid sugar, sucrose), acidulants, fragrances, powdered green tea powder, emulsifiers that improve texture, collagen, all Fat milk powder, thickening polysaccharides, agar (in the case of jelly drinks), amino acids other than the above-mentioned 5, 8 or 12 amino acids, vitamins, eggshell calcium, calcium pantothenate, other minerals, royal jelly , Propolis, honey, dietary fiber, agaricus, chitin, chitosan, herbal medicine, chondroitin, capsaicin, and the like, which are usually used as components of health foods.
8種のアミノ酸を含有する、上記経口アミノ酸ニキビ治療剤は、5種のアミノ酸を含有する、上記経口アミノ酸ニキビ治療剤に含有される5種のアミノ酸に加え、L−プロリン、Dおよび/またはL−アラニンおよびグリシンの3種を含む。これら3種のアミノ酸はコラーゲンの構成アミノ酸として特徴的なことから、皮膚真皮の状態を改善し、ニキビの治療にさらなる効果をもたらすものである。 The therapeutic agent for oral amino acid acne containing 8 amino acids is added to the 5 amino acids contained in the therapeutic agent for oral amino acid acne containing 5 amino acids, in addition to L-proline, D and / or L -Contains 3 types of alanine and glycine. Since these three amino acids are characteristic as constituent amino acids of collagen, they improve the state of the skin dermis and bring about further effects in the treatment of acne.
12種のアミノ酸を含有する、上記経口アミノ酸ニキビ治療剤は、5種のアミノ酸を含有する、上記経口アミノ酸ニキビ治療剤に含有される5種のアミノ酸に加え、必須アミノ酸6種と非必須アミノ酸1種を含む。つまり、必須アミノ酸9種全てとL−アルギニン、L−グルタミンおよびL−プロリンを含むことから、栄養価が高く、皮膚の新陳代謝を改善し、ニキビの治療にさらなる効果をもたらすものである。 The above-mentioned oral amino acid acne treatment agent containing 12 kinds of amino acids contains 5 kinds of amino acids, 5 kinds of amino acids contained in the above-mentioned treatment form of oral amino acid acne, 6 essential amino acids and 1 non-essential amino acid 1 Including species. That is, since it contains all nine essential amino acids and L-arginine, L-glutamine and L-proline, it has high nutritional value, improves skin metabolism, and has further effects on acne treatment.
本発明の経口アミノ酸ニキビ治療剤の製品形態には特別の制限はなく、経口摂取(摂食)できる形態であればいずれの形態でもよい。このような形態としては、適当な賦形剤を使用した粉末、顆粒、タブレット、液体(飲料、ゼリー飲料など)、キャンディ(チョコレートなど)等を挙げることができる。製品形態の極端な場合としては、上記5種、8種又は12種のアミノ酸の上記割合の単なる粉体混合物(粉末)を挙げることができる。粉末の場合は、直接粉薬のようにそのまま水で飲んでもよいし、またオブラートに包んで飲むこともでき、あるいは水、牛乳、ジュースなどに溶解して飲むこともできる。 There are no particular limitations on the product form of the therapeutic agent for oral amino acid acne of the present invention, and any form may be used as long as it can be taken orally. Examples of such forms include powders, granules, tablets, liquids (such as beverages and jelly beverages), and candy (such as chocolates) using appropriate excipients. As an extreme case of the product form, a simple powder mixture (powder) of the above-mentioned ratio of the above-mentioned 5, 8, or 12 amino acids can be mentioned. In the case of powder, it can be taken directly with water like a powder, or it can be taken by wrapping it in an oblate, or it can be taken by dissolving in water, milk, juice or the like.
本発明によるニキビ治療効果は、後記実験例1の結果を考慮して、5種のアミノ酸を必須成分として含有する、上記経口アミノ酸ニキビ治療剤に含有される5種のアミノ酸に着目して、これらのアミノ酸を上記割合で1日当りの合計で4g以上摂取することで奏せしめ得る。これより少量では目的の効果が奏されない。一方、過剰に摂取しても効果の向上は見込まれないので、1日当りの摂取量はこれら5種のアミノ酸を最大約12gとすることができる。このような範囲に含まれる量として、例えば、後掲実験例1にみられる5〜7g程度/日を好ましい量として挙げることができる。従って、本発明の経口アミノ酸ニキビ治療剤の製品における必須成分であるアミノ酸の含有量は、1日当りの摂取回数も考慮して、適宜このような摂取量を満足せしめることのできる量とすればよい。 The acne treatment effect according to the present invention focuses on the five amino acids contained in the above-mentioned oral amino acid acne treatment agent, which contains five amino acids as essential components in consideration of the results of Experimental Example 1 described below. Can be achieved by ingesting 4 g or more of the above amino acids in the above ratio in total per day. If the amount is less than this, the desired effect is not achieved. On the other hand, even if it is excessively consumed, the effect is not expected to be improved, so the daily intake can be up to about 12 g of these five amino acids. As an amount included in such a range, for example, about 5 to 7 g / day seen in Experimental Example 1 described below can be cited as a preferable amount. Therefore, the content of the amino acid, which is an essential component in the product of the therapeutic agent for oral amino acid acne of the present invention, may be appropriately determined in consideration of the number of intakes per day. .
次に、本発明のキットの形態のニキビ治療剤について説明する。 Next, the acne therapeutic agent in the form of a kit of the present invention will be described.
このキットの形態のニキビ治療剤は、本発明の経口ニキビ治療剤と適宜市販の外用ニキビ治療剤とを組み合わせてキットとしたもので、使用者にとって購入時に便である。 The acne treatment agent in the form of this kit is a combination of the oral acne treatment agent of the present invention and a commercially available external acne treatment agent as appropriate, which is convenient for the user at the time of purchase.
最後に本発明のニキビ治療方法について説明する。 Finally, the acne treatment method of the present invention will be described.
この方法は、本発明の経口ニキビ治療剤を経口摂取し、同時に外用ニキビ治療剤を外用することで、いわば体の内外からニキビの治療を行う方法であって、経口摂取および外用のいずれか一方に拠る場合に較べてニキビ治療効果に優れる方法である。 This method is a method of treating acne from the inside or outside of the body by orally ingesting the therapeutic agent for oral acne of the present invention and simultaneously applying the therapeutic agent for external use. It is a method that is more effective in treating acne than when it is based on.
以下、試験例により本発明を更に詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to test examples.
試験例1(ニキビ患者に対するアミノ酸投与試験)
(1)試験の概要:
(a)ニキビ患者を対象に、アミノ酸摂取によるニキビ症状に対する有用性を検討した。
Test Example 1 (Amino Acid Administration Test for Acne Patients)
(1) Outline of the test:
(A) In acne patients, the usefulness of acetic acid against acne symptoms was examined.
(b)被験者は、年齢20歳から45歳の38名で平均年齢28.6歳であり、自己申告によるニキビの数が頬部及び顎部に炎症性及び非炎症性皮疹が合わせて10個以上認められる者を対象とした。 (B) The subjects were 38 people aged 20 to 45 years, the average age was 28.6 years, and the number of acne self-reported was 10 inflammatory and non-inflammatory rashes on the cheeks and jaws. For those who were recognized above.
(c)試験は、1日3回毎食後に「アミノバイタル」(味の素(株)アミノ酸製剤、L−アルギニン、L−グルタミン、L−バリン、L−イソロイシンおよびL−ロイシンの5種)またはそのプラセボ品を1袋ずつを8週間摂取し(1日量:前記5種のアミノ酸6.6g)、試験開始前、4週間後、そして8週間後に来院し、全顔と左右頬の写真撮影を行った。 (C) The test was performed after 3 meals a day, after “Amino Vital” (Ajinomoto Co., Inc. amino acid preparation, L-arginine, L-glutamine, L-valine, L-isoleucine and L-leucine) or a placebo product thereof. Was taken for 8 weeks (daily dose: 6.6 g of the above 5 amino acids), visited before, 4 and 8 weeks after the start of the study, and photographed the whole face and left and right cheeks. .
(d)皮膚科医が撮影した写真によりニキビの状態を0〜5の6段階でランク付けしたところ、アミノ酸摂取群(Aグループ)では摂取開始4週間後の写真で、改善したものが7例、不変だったものが8例、そして悪化したものが4例認められた。また、アミノ酸摂取開始8週間後の写真で、改善したものが10例、不変だったものが8例、そして悪化したものが1例認められた。後掲第3表参照。これに対し、プラセボ摂取群(Bグループ)では摂取開始4週間後の写真で、改善したものが1例、不変だったものが13例、そして悪化したものが5例認められ、また摂取開始8週間後の写真で、改善したものが4例、不変だったものが11例、そして悪化したものが4例認められた。後掲第2表参照。 (D) Acne status was ranked in 6 levels from 0 to 5 according to photos taken by dermatologists. In the amino acid intake group (Group A), 7 photos improved after 4 weeks from the start of intake. There were 8 cases that remained unchanged and 4 cases that worsened. In addition, in the photograph 8 weeks after the start of amino acid intake, 10 cases improved, 8 cases remained unchanged, and 1 case worsened. See Table 3 below. In contrast, in the placebo ingestion group (Group B), 4 weeks after the start of ingestion, 1 case improved, 13 cases remained unchanged, and 5 cases worsened. Four weeks later, there were 4 cases that improved, 11 cases that remained unchanged, and 4 cases that deteriorated. See Table 2 below.
(e)以上の結果から、本発明の経口アミノ酸ニキビ治療剤の効果は有意に認められた。 (E) From the above results, the effect of the therapeutic agent for oral amino acid acne of the present invention was significantly recognized.
(2)試験の詳細:
(a)被験者:
38名の被験者をニキビの症状が均等になるように19名からなるAグループと19名からなるBグループの2グループに分けた。Aグループはアミノ酸を摂取する群であり、Bグループはアミノ酸を含まないプラセボ品を摂取する比較対照群である。
(2) Test details:
(A) Subject:
The 38 subjects were divided into two groups, group A consisting of 19 people and group B consisting of 19 people, so that acne symptoms were equalized. Group A is a group that takes amino acids, and Group B is a comparative control group that takes placebo products that do not contain amino acids.
なお、被験者に対して、試験の内容を十分説明し、本人の同意を得た上で試験を実施した。さらに、上記38名の被験者の選択に際しては、本試験の評価影響を及ぼすと考えられる疾患を合併している女性、妊産婦および授乳中の女性、および本試験実施計画書の規定の遵守が出来ない女性は除外した。また、制限事項として、試験結果に影響を及ぼすと考えられる例えばアミノ酸サプリメントを常用していることを挙げることができる。 In addition, the test content was fully explained to the subjects, and the test was conducted after obtaining the consent of the person. In addition, when the subject of the selection of the 38 people is, it can not comply with the provisions of this test women who have merged the disease which is considered the evaluation affect of, pregnant women and lactating women, and this study implementation plan Women were excluded. Moreover, as a restriction | limiting matter, it can mention mentioning that the amino acid supplement which is considered to affect a test result is used regularly.
(b)試験のスケジュール:
試験製品の摂取期間は8週間とし、被験者は、下記第1表に示すスケジュールにて試験を行うものとした。
(B) Test schedule:
The intake period of the test product was 8 weeks, and the subjects were to perform the test according to the schedule shown in Table 1 below.
(c)供試製品の服用方法:
供試製品は、1日3回毎食後に前記アミノ酸製剤「アミノバイタル」(1日量:前記5種のアミノ酸6.6g)もしくはアミノ酸を含まず他の成分は全く一緒であるプラセボ品を1袋づつ摂取するものとした。
(C) How to take the test product:
The product under test is the amino acid preparation “Amino Vital” (daily amount: 6.6 g of the above 5 types of amino acids) or a placebo product that does not contain amino acids and contains all other ingredients after each meal 3 times a day. Ingested.
ここに、Aグループが摂取したアミノ酸製剤「アミノバイタル」は、1袋4.5g中、前記5種のアミノ酸を計2.2gを含み、それらのアミノ酸の重量比は、L−アルギニン 23:L−グルタミン 25:L−バリン 14:L−イソロイシン 17:L−ロイシン 21であった。 Here, the amino acid preparation “Amino Vital” ingested by Group A contains a total of 2.2 g of the above five amino acids in 4.5 g of one bag, and the weight ratio of these amino acids is L-arginine 23: L- Glutamine 25: L-valine 14: L-isoleucine 17: L-leucine 21.
(d)写真撮影及び被験者日誌:
(i)写真撮影:各来院日に全顔及び左右頬の写真を撮影し、ニキビの状態を皮膚科医が次の0〜6の6段階で判定した。
(D) Photography and subject diary:
(I) Photographing: Photographs of the entire face and left and right cheeks were taken on each visit day, and the acne condition was determined by the dermatologist in the following 6 levels of 0-6.
(ii)被験者日誌:ニキビおよび肌全般の状態についてスコア化し、症状の変化を観察した。 (Ii) Subject diary: scored for acne and general skin condition and observed changes in symptoms.
(e)試験結果:
(i)写真撮影:皮膚科医の判断結果を下記第2表および第3表にまとめた。
(E) Test results:
(I) Photography: Judgment results of dermatologists are summarized in Tables 2 and 3 below.
(ii)被験者評価:摂取4週間及び8週間後の被験者アンケート結果を下記第4表にまとめた。アミノ酸摂取群ではプラセボ群に対して、ニキビの目立ち方、ニキビの数、ニキビの赤み、ニキビの痕が試験開始時にくらべて改善している傾向にあるという評価が得られた。また、試験開始4週間後よりも8週間後の方が、各症状が改善しているという傾向が見られた。 (Ii) Subject evaluation: Subject questionnaire results after 4 weeks and 8 weeks of intake are summarized in Table 4 below. In the amino acid intake group, the placebo group was evaluated to show that acne prominence, acne count, acne redness, and acne scars tended to improve compared to the beginning of the study. In addition, there was a tendency that each symptom was improved 8 weeks later than 4 weeks after the start of the test.
本発明によれば、副作用のない、しかも体調を改善できるニキビ治療剤が容易に提供することができる。
ADVANTAGE OF THE INVENTION According to this invention, the acne therapeutic agent which has no side effect and can improve a physical condition can be provided easily.
Claims (4)
An acne treatment kit comprising a combination of the oral amino acid acne treatment agent according to any one of claims 1 to 3 and an external acne treatment agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004110487A JP4836044B2 (en) | 2004-04-02 | 2004-04-02 | Oral amino acid acne treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004110487A JP4836044B2 (en) | 2004-04-02 | 2004-04-02 | Oral amino acid acne treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005289938A JP2005289938A (en) | 2005-10-20 |
| JP2005289938A5 JP2005289938A5 (en) | 2007-05-31 |
| JP4836044B2 true JP4836044B2 (en) | 2011-12-14 |
Family
ID=35323287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004110487A Expired - Fee Related JP4836044B2 (en) | 2004-04-02 | 2004-04-02 | Oral amino acid acne treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4836044B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069462A (en) | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | Lack the dietary product of at least two nonessential amino acid |
| JP2023530235A (en) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス,インコーポレーテッド | Formulations for individualized treatment regimens |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616617A (en) * | 1995-11-27 | 1997-04-01 | Van Moerkerken; Arthur | Face pimples prevention method and compositions |
| EP2158907B1 (en) * | 1997-09-17 | 2015-08-05 | Strategic Science & Technologies, LLC | Topical administration of arginine for pain treatment |
| JPH11269034A (en) * | 1998-03-20 | 1999-10-05 | Shiseido Co Ltd | Skin prepafation for external use for improving acne |
| FR2778562B1 (en) * | 1998-05-14 | 2000-08-04 | Sephra | PHARMACEUTICAL, HYGIENIC AND / OR COSMETIC COMPOSITION CONTAINING SEAWATER AND ARGININE |
| JP2001224334A (en) * | 2000-02-16 | 2001-08-21 | Ajinomoto Co Inc | Beauty food containing amino acid |
| JP3827923B2 (en) * | 2000-06-20 | 2006-09-27 | 味の素株式会社 | Amino acid composition for improving hematopoiesis and nutritional status |
| US7338675B2 (en) * | 2002-05-10 | 2008-03-04 | Tsi Health Sciences, Inc. | Fenugreek seed bio-active compositions and methods for extracting same |
-
2004
- 2004-04-02 JP JP2004110487A patent/JP4836044B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005289938A (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016278939A1 (en) | Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne | |
| JPH11332527A (en) | Production of extract of edible swallow's nest and health food, cosmetic or the like containing edible bird's nest | |
| WO2013106570A1 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
| JP2011246387A (en) | Composition for maintenance of muscle force and improvement of joint function | |
| WO2015015149A1 (en) | Dietary supplement | |
| JP4836044B2 (en) | Oral amino acid acne treatment | |
| US20050032898A1 (en) | Oral amino acid composition | |
| JP2001224334A (en) | Beauty food containing amino acid | |
| JP7526363B2 (en) | Drug composition for treating or reducing alcohol hangover and its use | |
| JP2015050991A (en) | Health supplements | |
| JP2004099599A (en) | Oral amino acid hair grower, epilation inhibitor, method of hair restoration and method of epilation inhibition using them | |
| KR20190012943A (en) | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention | |
| JP7108992B1 (en) | Composition containing ingredient derived from pericarp of sea buckthorn | |
| CN100444878C (en) | Enhancing sexual desire and performance with meal from plants containing protein-bound tryptophan | |
| JP2022056677A (en) | Compositions for preventing or treating anemia, composition for preventing increase or decrease in blood hemoglobin concentration, and composition for preventing increase or decrease in red blood cell count in blood | |
| JP2005247738A (en) | Oral amino acid composition for improving skin state | |
| CN1046090C (en) | Cosmetic tea | |
| JP2005306761A (en) | Anti-cortisol agent and functional food containing anti-cortisol agent | |
| JP4704007B2 (en) | Skin moisture improver | |
| JP7421184B2 (en) | Agents for increasing and/or maintaining skin moisture content and skin oil content | |
| JP2015518860A (en) | Pharmaceutical composition and health functional food containing deer horn extract extracted at high temperature | |
| WO2010119804A1 (en) | Anti-mental fatigue agent | |
| KR20250151381A (en) | A combination of an isoflavone source and at least one natural extract to help treat, prevent, or improve cognitive symptoms associated with menopause. | |
| JPWO2018124202A1 (en) | Food composition for promoting sweating | |
| JP2007161703A (en) | Anti-fatigue compound, endurance enhancing compound, and food and drink containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070121 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100607 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100804 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110615 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110725 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110905 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110918 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141007 Year of fee payment: 3 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141007 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |